Michal Vrablik M.D., Ph.D. is a Professor of Internal Medicine at the 1st Faculty of Medicine, Charles University in Prague, the Czech Republic. His main interests include preventive cardiology, clinical lipidology, CVD risk reduction strategies.
He is the chairman of the Czech Atherosclerosis Society, member of board of the Czech Society of Internal Medicine and the chairman of the Czech Association of Preventive Cardiology of the Czech Society of Cardiology. He is the head of the National centre of the FH screening MedPed program.
He served as a member of the Executive Committee of the European Atherosclerosis Society between 2012 and 2016.He closely cooperates with the International Atherosclerosis Society being the chair of IAS Regional Federation for Europe since January 2019. Since 2010 Dr. Vrablik has co-organized International Atherosclerosis Research School endorsed by the EAS and IAS.
Dr. Vrablik has authored and co-authored more than 400 papers in peer-reviewed scientific journals. He is the sole author of three monographs and of 25 book chapters. He is also a member of editorial board as well as a reviewer for several national and international journals.


Industrial Breakfast Session - Disussion and Q&AIndustry Breakfast Session90th EAS Congress 2022Managing LDL-C through a clinician’s lens - Michal VrablíkIndustry Breakfast Session90th EAS Congress 2022Debate: Who needs injectable therapies for cholesterol lowering? Statins and ezetimibe are enough for CVD prevention - Discussion and Q&A90th EAS Congress 2022ESC/EAS joint session: A deep dive into Prevention GLs with focus on dyslipidemiaHow to implement this personalised approach?90th EAS Congress 2022ESC/EAS joint session: A deep dive into Prevention GLs with focus on dyslipidemiaCan combination aid adherence ? (fixed dose, intolerance)88th EAS Congress 2020Fibrates in the management of AD and CVD risk85th EAS Congress 2017